{
    "eid": "2-s2.0-85165282732",
    "title": "BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines",
    "cover-date": "2023-08-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pathology and Forensic Medicine",
            "@code": "2734",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cell Biology",
            "@code": "1307",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Apoptosis",
        "BI6727",
        "Cholangiocarcinoma",
        "GSK461364A",
        "Mitotic catastrophe",
        "PLK1",
        "Volasertib"
    ],
    "authors": [
        "Handy Riantana",
        "Orawan Waenphimai",
        "Panupong Mahalapbutr",
        "Kun Karnchanapandh",
        "Kulthida Vaeteewoottacharn",
        "Sopit Wongkham",
        "Kanlayanee Sawanyawisuth"
    ],
    "citedby-count": 0,
    "ref-count": 26,
    "ref-list": [
        "Reversine, a selective MPS1 inhibitor, induced autophagic cell death via diminished glucose uptake and ATP production in cholangiocarcinoma cells",
        "Multiple actions of NMS-P715, the monopolar spindle 1 (MPS1) mitotic checkpoint inhibitor in liver fluke-associated cholangiocarcinoma cells",
        "Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients",
        "Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC",
        "Present and future perspective on PLK1 inhibition in cancer treatment",
        "The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation",
        "PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer",
        "BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity",
        "Spotlight on volasertib: preclinical and clinical evaluation of a promising Plk1 Inhibitor",
        "Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1",
        "A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis",
        "The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations",
        "Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies",
        "Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100)",
        "Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient",
        "Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity",
        "Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells",
        "Kinome-wide screening with small interfering RNA identified polo-like kinase 1 as a key regulator of proliferation in oral cancer cells",
        "Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer",
        "Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel",
        "Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma",
        "In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors",
        "Tubulintracker, a novel in vitro reporter assay to study intracellular microtubule dynamics, cell cycle progression, and aneugenicity",
        "Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy",
        "BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells",
        "Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60026046",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Faculty of Medicine , KKU",
        "NSRF-KKU",
        "Khon Kaen University",
        "National Research Council of Thailand",
        "Faculty of Medicine, KKU"
    ]
}